Companys like Stifel and MS have been buying stock as of march 31.... see the nasdaq institutional print for institutions. How nice to be able to downgrade the stock and then start buying it.
Just thinking - is this some kind of brand new item thats never been tested or verified. I would assume there are many commonly used "excipents" that are well known and proven in the drug world. Couldn't this have been known like 18 months ago?
Maybe that's not the case with a new drug or mixture - but it seems odd that i have never once heard of this from any other drug company ever ?? (and i am long time holder of rmti)
saw that too, but very amazed that that alone would destroy the stock and that these prices have zero interest now. even insiders that bought open market at 4$ in Aug. have no interest at .80 cents.
PTx. they have alot of debt, and have issued a ton of stock to finance 2 convertible issues. so dilution is out there in there plan. ADD into this they have 2 shelf offerings to issue more stock in the future... TBD.... that hangs over there plans.
i think this is way the stock is being crushed, because those close to the stituation can see when they need to issue more stock to raise more money (they would greatly prefer to have to issue stock at these super low prices, so they can take advantage of stockholders.)
just scan the 10K from March
no one wants this in their book. all sellers no buyers........
not usual for a micro cap like bio. Earnings in 2 weeks. any real news brewing other than speculation??
the BIG volume that pushed us over 1.20 was at least 1 great technical sign of maybe more to come...
it takes just a few minutes to review. Cash position good thru 2016. 2 rounds of stock issued convert into shares at either 1.5 or 2.33 . give it a quick scan, has good info in it
Liquidity and Capital Resources
As of December 31, 2015, BIOLASE had approximately $19.7 million in working capital. Cash and restricted cash equivalents at the end of the fourth quarter 2015 were $11.9 million, as compared to $31.6 million on December 31, 2014. Net accounts receivable totaled $8.9 million at December 31, 2015, as compared to $9.0 million at December 31, 2014.
Chief Financial Officer David Dreyer commented, “Cash preservation continues to be a top priority for management, and we were pleased that our cash used in operating activities during this recent fourth quarter was $2.8 million, which was our lowest level used over the past 6 quarters. While the Company ended up using $3.5 million of cash during the fourth quarter of 2015, this amount included paying out a $1.5 million settlement.” Dreyer added, “We are also starting a search process to obtain credit financing in order to help bolster our cash position in 2016.”
debt over 2x the current market capitalization. this is more than just an earnings issue. Can someone elaborate the finance structure and why the valuation seems way off balance???